# About Reviews Reta — Retatrutide Research Digest

> Reviews Reta is an independent editorial project that publishes plain-language summaries of the published retatrutide research. Not a clinic, not a vendor, not a prescriber.

An independent editorial project that reviews the published retatrutide research in plain language.

## What this site is

Reviews Reta is an independent editorial project that publishes plain-language summaries of the peer-reviewed research literature on retatrutide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The name reflects what we do: we read the research on retatrutide and review it for a general audience. "Reviews" is not a claim to be a clinical review service or a licensed reviewer — it is a description of the editorial act: reading the studies, weighing the evidence, and writing it up in language a non-scientist can follow.

The site was built because retatrutide is one of the most-searched investigational compounds in the world right now — driven by its unusually large Phase 2 trial results — and a substantial portion of what appears in search results conflates investigational data with availability claims, mixes anecdotal reports with clinical findings, or omits material safety considerations. We aim to be the cleaner alternative: here is what the trials actually measured, labeled accurately, with every number cited.

## What we cover and how

This site covers: the mechanism of action; Phase 1, 2, and 3 trial results; the safety profile as documented in the published literature; community-reported effects (clearly labeled as anecdotal and not clinical evidence); safety cautions grounded in the trial and regulatory record; and the current regulatory and availability status.

We do not cover: dosing advice or instructions for obtaining retatrutide outside a clinical trial. We do not link to sources for obtaining the compound. We do not speculate on approval timelines beyond what Eli Lilly and registered trial filings have stated.

Every quantitative claim on this site is cited inline with a numbered reference that points to a DOI or PubMed URL. If a number is not cited, it should not appear here. If you find an uncited number, the contact page is the right place to flag it.

## Retatrutide availability and cost

Retatrutide is an investigational compound not approved by any regulator as of 2026. It is not commercially available. It cannot be prescribed. There is no list price.

This is not a temporary caveat that will lift soon — it is the current factual status of a compound in Phase 3 clinical trials. We will update this page when the regulatory picture changes, but as of the writing of this page, the answer to "where can I get retatrutide" is: enrolled clinical trial only.

For current trial locations and eligibility criteria, ClinicalTrials.gov maintains an updated list of TRIUMPH and related retatrutide trials. We do not maintain that list.

## Editorial standards

We write every page from primary sources — the published clinical trial papers and peer-reviewed reviews listed in our [retatrutide references](/references). We do not write content from secondary sources (news articles, company press releases, forum posts) unless the content is clearly labeled as community signal rather than clinical evidence.

The [effects and safety](/effects) page follows a specific structure: benefits are reported first, then adverse effects, then safety cautions grounded in mechanism and clinical data. Community signals are grouped separately under a visible "anecdotal, not clinical evidence" label. No dose accompanies any community signal. This structure is designed to be useful to a reader weighing the compound without misleading them about the strength of any particular piece of evidence.

---

Plain-language reviews of published investigational trial evidence — not a clinical service, not a vendor, not an endorsement.